XML 13 R2.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
ASSETS    
Cash and cash equivalents $ 14,424 $ 10,299
Marketable securities 23,946 32,754
Prepaid and other current assets 1,276 1,053
Total current assets 39,646 44,106
Property and equipment, net 148 165
Other assets 1,494 309
Total assets 41,288 44,580
Liabilities    
Accounts payable 553 762
Accrued liabilities 4,548 4,857
Total current liabilities 5,101 5,619
Other long-term liabilities 1,729 1,507
Total liabilities 6,830 7,126
Commitments and Contingencies
Stockholders' Equity    
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2019 and December 31, 2018, respectively 0 0
Common stock, $0.001 par value, authorized 500,000,000 shares; issued and outstanding, 10,393,312 and 9,865,735 shares at March 31, 2019 and December 31, 2018, respectively 10 10
Additional paid-in capital 437,850 436,433
Treasury stock, at cost; 11,080 shares at March 31, 2019 and December 31, 2018 (708) (708)
Accumulated deficit (402,406) (397,977)
Accumulated other comprehensive loss (18) (32)
Total Caladrius Biosciences, Inc. stockholders' equity 34,728 37,726
Noncontrolling interests (270) (272)
Total stockholders' equity 34,458 37,454
Liabilities and Equity, Total $ 41,288 $ 44,580